-
MPii Projects’ Technical Presence at AIDS 2018
July 18, 2018- | Featured
Three MPii projects showcased their evidence-based work at AIDS 2018 in Amsterdam, from July 21 – 27, 2018.
-
OPTIONS Completes First Plan 4 PrEP Learning Collaborative
In March 2018, OPTIONS completed its first Plan 4 PrEP Learning Collaborative (P4P LC) with six participating countries—Botswana, Mozambique, Namibia, Tanzania, Uganda, and Zambia.
-
GEMS Launches Toolkit Focused on HIV Drug Resistance
Photo Credit: GEMS Project
The Global Evaluation of Microbicide Sensitivity (GEMS) project has developed a toolkit focused on HIV drug resistance within PrEP rollout programs. These toolkit materials are designed to help policymakers, health care workers, and laboratory personnel develop and implement drug resistance monitoring programs.
-
The OPTIONS Consortium objective is to develop a streamlined, adaptable product delivery platform for current and future ARV-based HIV prevention options, with a particular focus on women.
- OPTIONS develops communication strategy for Lesotho’s oral PrEP roll out.
- OPTIONS hosts dapivirine ring modeling stakeholder consultation.
- Operations research underway.
- PrEPWatch re-organized and new resources added.
- Mapping of PrEP trials and implementation projects updated.
-
POWER develops cost-effective and scalable models for implementation of ARV-based HIV prevention products for women.
- Cohorts in Cape Town, Johannesburg, and Kisumu enroll more than 200 young women.
- My PrEP decision support tool ready to launch; additional demand creation tools in development.
- POWER team meeting convened.
-
CHARISMA supports efforts to: increase women’s agency to safely use ARV-based HIV prevention, to engage male partners in HIV prevention, and to overcome harmful gender norms and reduce intimate partner violence (IPV).
- Clinic-based intervention continues.
- Community-based intervention completed in September.
- CHARISMA pilot evaluation underway and effectiveness study planned.
-
EMOTION increases uptake and correct and consistent use of ARV-based HIV prevention products by women at high risk of HIV infection using an end-user centered strategy.
- Project VOGUE continues.
-
GEMS informs policies and defines programmatic considerations related to use of ARV-based HIV prevention products and risk of resistance.
- Genital swabs testing begins and assay development is underway.
- Drug resistance testing in Kenya progresses.
- Drug resistance testing in South Africa planned.
- Collaboration in Zimbabwe begins.
- GEMS to offer technical assistance on drug resistance testing.
- Oral PrEP modeling progresses.